SF
GILD icon

Synovus Financial’s Gilead Sciences GILD Stock Holding History

Synovus Financial’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-42,500
Closed -$3.02M – 932
2014
Q1 		$3.02M Buy
+42,500
New +$3.33M 0.09% 128

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Synovus Financial's GILD Position: Q3 2025 in Review

Synovus Financial reduced its Gilead Sciences (GILD) stake by 0.06% in Q3 2025, selling an estimated $1.36K and leaving 21,094 shares worth $2.34M. The position accounts for 0.03% of the portfolio, ranked #336.

Synovus Financial first reported a position in GILD in Q2 2013 and has held it in 50 quarters since. The position peaked at $9.96M in Q4 2015. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Synovus Financial held 21,094 shares of Gilead Sciences worth $2.34M as of Q3 2025.
  • Synovus Financial sold 12 Gilead Sciences shares in Q3 2025, an estimated $1.36K.
  • Gilead Sciences made up 0.03% of Synovus Financial's portfolio in Q3 2025, its #336 holding.
  • Synovus Financial first reported a position in Gilead Sciences in Q2 2013 and has held it in 50 quarters since.
  • Synovus Financial's Gilead Sciences position peaked at $9.96M in Q4 2015.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.